These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20063904)

  • 1. Regadenoson.
    Garnock-Jones KP; Curran MP
    Am J Cardiovasc Drugs; 2010; 10(1):65-71. PubMed ID: 20063904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in pharmacologic stress agents: focus on regadenoson.
    Johnson SG; Peters S
    J Nucl Med Technol; 2010 Sep; 38(3):163-71. PubMed ID: 20724531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regadenoson: a new myocardial stress agent.
    Al Jaroudi W; Iskandrian AE
    J Am Coll Cardiol; 2009 Sep; 54(13):1123-30. PubMed ID: 19761931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of pharmacologic stress: selective A2A adenosine receptor agonists.
    Cerqueira MD
    Am J Cardiol; 2004 Jul; 94(2A):33D-40D; discussion 40D-42D. PubMed ID: 15261132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regadenoson (CV Therapeutics/Astellas).
    Eggbrecht H; Gössl M
    Curr Opin Investig Drugs; 2006 Mar; 7(3):264-71. PubMed ID: 16555687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics.
    Mekkaoui C; Jadbabaie F; Dione DP; Meoli DF; Purushothaman K; Belardinelli L; Sinusas AJ
    JACC Cardiovasc Imaging; 2009 Oct; 2(10):1198-208. PubMed ID: 19833310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole.
    Friedman M; Spalding J; Kothari S; Wu Y; Gatt E; Boulanger L
    J Med Econ; 2013; 16(4):449-60. PubMed ID: 23363331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist.
    Zhao G; Messina E; Xu X; Ochoa M; Sun HL; Leung K; Shryock J; Belardinelli L; Hintze TH
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):369-75. PubMed ID: 17577101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications.
    Palani G; Ananthasubramaniam K
    Cardiol Rev; 2013; 21(1):42-8. PubMed ID: 22643345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.
    Gordi T; Blackburn B; Lieu H
    J Clin Pharmacol; 2007 Jul; 47(7):825-33. PubMed ID: 17585115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
    Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myocardial infarction during regadenoson myocardial perfusion imaging.
    Shah S; Parra D; Rosenstein RS
    Pharmacotherapy; 2013 Jun; 33(6):e90-5. PubMed ID: 23471769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regadenoson in the detection of coronary artery disease.
    Buhr C; Gössl M; Erbel R; Eggebrecht H
    Vasc Health Risk Manag; 2008; 4(2):337-40. PubMed ID: 18561509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regadenoson-stress myocardial CT perfusion and single-photon emission CT: rationale, design, and acquisition methods of a prospective, multicenter, multivendor comparison.
    Cury RC; Kitt TM; Feaheny K; Akin J; George RT
    J Cardiovasc Comput Tomogr; 2014; 8(1):2-12. PubMed ID: 24314823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.
    Cerqueira MD; Nguyen P; Staehr P; Underwood SR; Iskandrian AE;
    JACC Cardiovasc Imaging; 2008 May; 1(3):307-16. PubMed ID: 19356442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats.
    Dhalla AK; Wong MY; Wang WQ; Biaggioni I; Belardinelli L
    J Pharmacol Exp Ther; 2006 Feb; 316(2):695-702. PubMed ID: 16227469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial.
    Gaemperli O; Schepis T; Koepfli P; Siegrist PT; Fleischman S; Nguyen P; Olmsted A; Wang W; Lieu H; Kaufmann PA
    J Am Coll Cardiol; 2008 Jan; 51(3):328-9. PubMed ID: 18206744
    [No Abstract]   [Full Text] [Related]  

  • 18. Regadenoson.
    Bengalorkar GM; Bhuvana K; Sarala N; Kumar TN
    J Postgrad Med; 2012; 58(2):140-6. PubMed ID: 22718059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regadenoson stress for myocardial perfusion imaging.
    Reyes E
    Future Cardiol; 2016 Jan; 12(1):59-67. PubMed ID: 26639775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intravenous adenosine and intravenous regadenoson for the measurement of pressure-derived coronary fractional flow reserve.
    Arumugham P; Figueredo VM; Patel PB; Morris DL
    EuroIntervention; 2013 Feb; 8(10):1166-71. PubMed ID: 23164748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.